Dash Bio, a pioneering company in the field of bioanalysis, has successfully raised an additional $11 million in funding, increasing its total capital to $17.5 million. This new investment, announced on July 23, 2025, was spearheaded by The Aligned Fund, with contributions from notable investors including Freestyle Capital, Cybernetix Ventures, Swift Ventures, and LifeX Ventures.
The company operates out of Newton, Massachusetts, where it has developed a fully automated, Good Laboratory Practice (GLP)-compliant bioanalysis platform. This innovation aims to transform the drug development process, which traditionally spans 7 to 12 years and costs billions. Dash Bio seeks to address the inefficiencies of this phase, which often remains slow and heavily reliant on manual labor.
Dash Bio’s model offers a refreshing alternative to the conventional outsourcing practices prevalent in the industry. Currently, over 70% of drug development work is farmed out to Contract Research Organizations (CROs), whose labor-intensive processes can hinder progress. By contrast, Dash Bio delivers assays such as ELISA, LC-MS, and qPCR at speeds up to 10 times faster than existing providers, enabling drug developers to accelerate their journey from concept to Investigational New Drug (IND) application and ultimately to market approval.
According to Dave Johnson, co-founder and CEO of Dash Bio, this funding reflects a significant shift in the industry. “We founded Dash because the broken state of development is one of the biggest threats to progress in biotech. Our platform was designed the right way from day one: real automation, real integration, and real science,” he stated. Johnson, previously the Chief Data & AI Officer at Moderna, emphasized the urgency of adopting a new standard in bioanalysis that can serve as a catalyst for innovation.
The company has quickly gained traction, attracting top-tier biopharmaceutical companies as clients and assembling a team of experts from leading organizations, including Moderna and Science Exchange. This diverse group brings extensive knowledge in bioanalysis, software engineering, and lab automation, positioning Dash Bio to enhance efficiency in drug development significantly.
“Ariel Winton-Jones,” a Partner at The Aligned Fund, expressed confidence in Dash Bio’s potential, stating, “Dash Bio isn’t just faster — it’s foundational. Their team has built the kind of tech-forward infrastructure that biotech has needed for years. We believe Dash is creating the modern stack for bioanalysis and beyond.”
With the latest round of funding, Dash Bio plans to further scale its automated platform, broaden its assay offerings, and invest in its proprietary sample and assay management software. The company aims to onboard new customers across various stages of clinical development, from preclinical to late-stage trials.
Dash Bio stands at the forefront of a critical evolution in drug development, committing to deliver high-quality, technology-driven bioanalysis at unprecedented speeds. By integrating robotics, artificial intelligence, and advanced software, the company seeks to help biopharma teams bring therapies to patients more efficiently. For more information, visit www.dash.bio.
